RxDoctor Payments Data

Paul Chu, MD

Cardiovascular Disease · Independence, MONPI 1477558658

Payments from drug & device makers

$11,004in general payments, 2019–2025

Across 550 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$2K
  • Amgen$1K
  • Johnson & Johnson$905
  • Novartis$898
  • Boston Scientific$785
  • E.r. Squibb & Sons, L.L.C.$619
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$200%
  • Travel & lodging$1,10510%
  • Food & beverage$9,77389%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,004 in reported general payments places this provider in the 70th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$155,769
Medicare patients
1,252
Services billed
2,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban295$333,541
XareltoRivaroxaban166$204,084
EntrestoSacubitril/Valsartan56$72,843
JardianceEmpagliflozin60$66,641
Repatha SureclickEvolocumab35$43,127
BrilintaTicagrelor16$17,221
Praluent PenAlirocumab11$13,619
Repatha SyringeEvolocumab21$11,884
NexlizetBempedoic Acid/Ezetimibe24$9,416
Ranolazine ErRanolazine49$7,058
Metoprolol Succinate472$6,016
Ezetimibe317$5,086
Atorvastatin Calcium476$4,886
Dabigatran EtexilateDabigatran Etexilate Mesylate26$4,636
Rosuvastatin Calcium311$3,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$454$333,541295 claims
Johnson & JohnsonXarelto$905$204,084166 claims
NovartisEntresto$898$72,84356 claims
Boehringer IngelheimJardiance$395$66,64160 claims
AstraZenecaBrilinta, Crestor$253$20,16627 claims
Esperion Therapeutics, Inc.Nexlizet$50$9,41624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →